Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum WPD Pharmaceuticals Inc WPDPF


Primary Symbol: C.WBIO

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

CSE:WBIO - Post Discussion

WPD Pharmaceuticals Inc > WPD and Moleculin could...
View:
Post by Blocky on Jan 10, 2021 10:50am

WPD and Moleculin could...

WPD and Moleculin could be  worth over 300 million? Only because of one drug? 

https://ir.moleculin.com/press-releases/detail/201/moleculin-announces-fda-approves-3-rare-pediatric-disease

Mr. Klemp, Chairman and CEO of Moleculin, said: "...It is also important for investors to understand the implications of the PRVs or Priority Review Vouchers.  These vouchers are issued upon drug approval of the rare disease indication from the FDA and, once issued, can be transferred to other drug developers.  These PRVs have historically had tremendous value and have been recently sold for up to $100 million or more.  For Moleculin to have the potential for three of them is noteworthy indeed."

https://ir.moleculin.com/press-releases/detail/201/moleculin-announces-fda-approves-3-rare-pediatric-disease
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities